Identification of new putative driver mutations and predictors of disease evolution in chronic lymphocytic leukemia by Mosquera Orgueira, Adrián et al.
Mosquera Orgueira et al. Blood Cancer Journal            (2019) 9:78 
https://doi.org/10.1038/s41408-019-0243-3 Blood Cancer Journal
CORRESPONDENCE Open Ac ce s s
Identification of new putative driver mutations and
predictors of disease evolution in chronic
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Dear Editor,
The analysis of hundreds of chronic lymphocytic leu-
kemia (CLL) exomes has shed new light on the hetero-
geneous genomic background characterizing this
disease1,2. At the same time, the increased availability of
exome-sequencing data comes along with a big bottleneck
in the interpretation of its results, which is related to the
remarkable heterogeneity in mutation detection between
different bioinformatic protocols. Differences in clonality,
purity, sequencing coverage, and quality constitue diffi-
culties for most variant callers. The methods with the
highest sensitivity are frequently accompanied by lower
precision, leading to remarkable differences in mutation
detection3–5. Therefore, we hypothesize that numerous
variants in large sequencing projects have passed
unnoticed.
Here, we report the results of a complementary analysis
performed on the International Cancer Genome Con-
sortium (ICGC) CLL cohort6. The final analysis included
49 monoclonal B cell lymphocytosis and 390 treatment-
naive CLL samples. Mutation detection was performed
with two different methods: VarsCan2, which uses a
heuristic/statistical method for variant detection; and
Platypus, which implements a Bayesian approach and
local realignment of reads for indel and complex mutation
detection. Variant quality was recalibrated using a logistic
model, and drivers were detected by integrating the
results of methods based on mutation frequency
(MuSiC2), functional impact (OncodriveFM), co-
localization (OncodriveClust and Mutation3D), and
pathogenicity prediction (VEST and CHASM) (Supple-
mentary Methods). Cox regression was used for survival
analysis. Assumption of proportional hazards was checked
with Schoenfeld’s method. An unadjusted model was used
to test the association of each mutated gene/pathway with
time to treatment and overall survival. Similarly, we cre-
ated an adjusted model which included variables asso-
ciated with outcomes of interest at a nomial p-value < 0.2
(IGHV status, sex, and stage at diagnosis for time to
treatment analysis; and IGHV status, age and stage at
diagnosis for overall survival analysis). In the case of
pathways analysis, the total number of mutations in genes
belonging to each pathway were used as input. P-values
were adjusted for multiple testing using the
Benjamini–Hochberg (BH) method.
A total of 28,350 mutations were detected in 439
treatment-naive patient samples, of which 12,057 affected
protein-coding regions (Supplementary Table 1). There
were 8,965 non-silent and 3,095 silent mutations. The
large majority of the non-silent mutations were missense
(7,558 events). Point mutations were the most frequent
(21,180), followed by short deletions (3,240) and inser-
tions (2,041). There were 1,888 multi-nucleotide muta-
tions (involving 2 or more consecutive nucleotides)
(Supplementary Fig. 1).
Sixty-six genes were detected as putative drivers (Fig. 1,
Supplementary Table 2, Supplementary Tables 3–8), of
which thirty-two had been previously described by Puente
et al.1 Among the novel ones, the most frequently muta-
ted were DTX1, LPHN3, LRP1B, LTB, and WDFY3.
LPHN2 and SI were mutated in six patients; BIRC6,
DOCK1, MLL3, PCDH15, PTPN13, PTPRM, RELN, and
TFEB were mutated in five patients and the remaining
putative drivers were mutated in four different cases.
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Furthermore, WDFY3 harbored two additional silent
mutations that are predicted to create new donor or
acceptor cryptic sites. BIRC6, DOCK1, KMT2C/MLL3,
PTPRB, and PTPRT were each affected by one silent
mutation predicted to create a new cryptic splice site.
Mutations in IGLL5 were frequent and located in hot-
spots, but they were accompanied by a high rate of silent
mutations. Finally, we observed that FREM1 was targeted
by four likely functional non-synonymous mutations and
two additional silent mutations in the same position. Most
of the new proposed drivers play well-defined roles in
carcinogenesis, such as EPHA7;7 MYCBP2;8 PTPRM9.
Other putative drivers have been linked to oncogenesis
before, such as the autophagy regulator WDFY310, the
Notch pathway gene DTX111, the latrophilin genes
LPHN2 and LPHN312, as well as FREM1, which encodes
the MYD88 and NFkB pathways related-protein TILRR13.
Similarly, driver mutations in CARD11 and SI have been
previously described in CLL2,14, and the genes BIRC6 and
KMT2C/MLL3 are paralogs of the CLL drivers BIRC3 and
KMT2D.
Low-frequency and likely pathogenic mutations in 60
genes (Supplementary Table 9) were detected. This type
of mutations affected known cancer drivers (EGFR,
ERBB4, MAP2K1, NF1, NFKB1, NOTCH3, and SRSF1),
including multiple drivers of lymphoproliferation such as
BAX, BCOR, BCR, BTG2, DIS3, IKZF3, KRAS, PPM1D,
PTPN11, SETD1B, TLR2, and TRAF3. The list also
includes regulators of lymphocyte pathways (CD19, CD36,
ALCAM) and of relevant cancer pathways such as the
Notch pathway (NOTCH3, DMXL2, and SBNO1), WNT/
β-catenin pathway (DACT1); DNA polymerization
(POLE) and epigenetic regulation (KDM5A, HIST1H1D,
PHF1 and single mutations at HIST1H2BC and
HIST1H2BG). Moreover, isolated missense mutations in
relevant oncogenes and tumor suppressor genes such as
EP300, KIT, MELK, and PTEN were among the most
significant events.
Non-synonymous mutations in 16 genes were sig-
nificantly associated with time to first treatment (q-value
< 0.1, Supplementary Table 10). The list included known
CLL drivers such as ATM, SF3B1, BRAF, NOTCH1,
BIRC3, IRF4, and ZMYM3, as well as other putative novel
drivers such as EPHA7 and SI. Mutations in IGLV3-21,
DOCK1, and EPHA7 were associated with time to treat-
ment after covariate adjustment (q-value < 0.1,
Fig. 1 Mutation plot representing the most frequent novel CLL drivers identified in this study. Plot indicating the number and type of
mutations in driver genes. Only drivers not described by Puente et al1. are represented
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Supplementary Table 11). In order to assess the potential
effect of silent mutations on time to treatment, we
included them in the regression, revealing new significant
associations in IGHV1-69, IGKJ5, IGHV2-70, and FAT1.
Furthermore, silent mutations in IGLV3-21 reduced the
association p-value further (Supplementary Figure 2).Only
two IGLV3-21 mutated cases co-expressed IGHV3-21,
indicating an independent role of the IGHV3-21/IGLV3-
21 stereotyped B cell receptor. This is in concordance
with a recent report about the adverse prognosis of
IGLV3-21 expression in CLL15. Finally, mutations in
ASXL1, ATM, IGHV1-69, SPEN, SF3F1, PLCH1, and
POT1 were associated with overall survival (q-value <
10%, Supplementary Table 12), but none of these was
Fig. 2 New prognostic biomarkers of CLL clinical evolution. a–b Kaplan–Meier plots indicating the association between mutations in the TP53
pathway and time to treatment with and without TP53 mutated cases (Fig. 2a, b, respectively). The red line indicates patients without mutation in this
pathway, whereas the green and blue lines indicate patients with one or more than one mutation, respectively. c–d Kaplan–Meier plots indicating
the association of mutations in the 3′ UTR and flanking region of IGKC with time to treatment. In Fig. 2c the red line indicates those patients without
mutations in this region and the blue line indicate mutated cases. Similarly, in Fig. 2d the blue line indicates IGHV mutated cases with mutation in
IGKC, the red line indicates IGHV mutated cases without IGKC mutation, the purple line indicates IGHV unmutated cases with IGKC mutation and the
green line indicates those patients with both unmutated IGHV and IGKC
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significant after covariate adjustment (q-value < 0.1; Sup-
plementary Table 13).
The genes IGLL5, LTB, ZFP36L1, LRP1B, and PCDH15
were significantly enriched in intronic mutations (q-value
< 0.1; Supplementary Table 14, Supplementary Table 15).
Mutations in ZFP36L1 and DAPK1 were independently
associated with time to first treatment (adjusted q-value <
0.1), whereas those in IGHV3-49 were independently
associated with overall survival (adjusted q-value < 0.1;
Supplementary Tables 16–19).
A pathway-level inquiry detected 62 terms enriched in
mutations (Bonferroni p-value < 0.1) (Supplementary Table
20). The most significantly mutated pathways were “RB
pathway”, “TP53 pathway”, “ATM pathway”, “Apoptotic
Signaling in Response to DNA Damage”, “TP53 Hypoxia
pathway” and the “G1 pathway”. Most of the significant
associations with clinical evolution were influenced by the
presence of frequent driver mutations within the pathway.
However, the following four significant pathways did not
include any high-frequency CLL-driver gene: “CDK5 path-
way”, “Apoptosis-induced DNA fragmentation”, “FRS2
mediated cascade”, and the “RAF MAP Kinase cascade”. We
detected an interesting pattern in the TP53 downstream
pathway, which affected ~10% of the patients. Mutations in
this pathway were strongly and independently associated
with shorter time to first treatment (p-value 3.80 × 10−5,
Fig. 2a, b, Supplementary Table 21), and removing TP53
mutated cases from the analysis did not affect the associa-
tion substantially (p-value 5.3 × 10−4). These mutations
were also significantly associated with lower overall survival
(p-value 2.81 × 10−4), but not independently of IGHV status
(p-value 0.54). These results suggest that the disruption of
the TP53 pathway plays an active role in CLL.
Finally, some analyzed non-coding regions located near
immunoglobulin-related genes exhibited a remarkable
mutation frequency. Mutations in the 3′ UTR of IGHV1-
69 were independently associated with lower time to
treatment (adjusted q-value < 0.1, 95% HR 1.09–4.33).
Furthermore, hypermutation events occurred in a 1,543
base pair region located in the 5′ flank and UTR region of
IGKC (172 patients, 40% of the total population, Supple-
mentary Tables 22–23). These mutations were strongly
associated with longer time to first treatment (p-value
7.23 × 10−11, HR 0.21–0.44; Fig. 2c) and were independent
of IGHV status, sex, and clinical stage at diagnosis
(p-value 6.3 × 10−3, q-value 3.7 × 10−2, HR 0.39–0.86;
Fig. 2d). Similarly, an association with longer overall
survival was detected (p-value 2.81 × 10−4), but not
independently of other covariates (p-value 0.54). This
region includes protein-coding sequences of some
immunoglobulin genes (namely IGKJ1, IGKJ2, IGKJ3,
IGKJ4, and IGJK5). Although these genes were mutated in
126 cases, most of them (96%) had concurrent mutations
in the surrounding non-coding region.
For mutation validation, we matched whole genome
sequencing data available in a subset of 88 samples which
was used. We could validate 94.38, 100, and 97.75%
mutations located in new putative exonic and intronic
drivers, as well as in 5′UTR region of IGKC, respectively
(Supplementary Table 24). Importantly, all non-
confirmed mutations were subclonal.
Some of our results need further clarification in
future approaches. Particularly, the frequency, func-
tional and clinical implications of the new putative
drivers needs to be replicated in independent cohorts.
Nevertheless, the novelty and relevance of some of our
results anticipate important implications in the biolo-
gical comprehension and prognostic stratification
of CLL.
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